NEW YORK (GenomeWeb) – Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery. The firms will integrate Genedata's Screener software with IntelliCyt's iQue Screener system.
The alliance will bring Genedata's highly-scalable data analytics to IntelliCyt's high-throughput flow cytometry capabilities. The iQue Screener can analyze more than 10,000 cells or beads per second, the firm said in a statement, an order of magnitude increase over plate-based systems, with up to 15 parameters per cell.
"Advanced computational analysis solutions are required to handle the quantity and complexity of data obtained in high-throughput flow cytometry experiments in large-scale screening applications," Janette Phi, chief business officer at Albuquerque, New Mexico-based IntelliCyt, said in a statement. "The combined solution of Genedata Screener software and the IntelliCyt iQue Screener platform addresses this unmet industry need. Our solution provides a powerful option for our customers for robust and accurate data analysis across all plates from high-throughput flow cytometry data generated by iQue."
The combined technologies will enable researchers to screen large libraries of drug candidates against suspension cells and multiplex beads in phenotypic drug discovery, antibody screening, immunology, and biomarker research, the firms said.
In November 2014 Takara Bio selected the Genedata Expressionist software platform to analyze next-generation sequencing data.